^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + ficerafusp alfa (BCA101) (EGFR inhibitor, TGFβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.
Published date:
05/25/2023
Excerpt:
This ongoing single-arm, open-label multicenter dose expansion cohort enrolled pts with R/M HNSCC with a tumor PD-L1 CPS≥1... The ORR in stage 1 was 44% (8 PRs, 4 SD) with a clinical benefit rate (CBR=PR+SD) of 67%; 7/12 (58%)...Stage 1 of this dose expansion cohort of BCA101+P shows encouraging anti-tumor activity with additive potential, particularly among HPV-neg pts; and the combination is well tolerated among this R/M HNSCC population.
DOI:
10.1200/JCO.2023.41.16_suppl.6005
Trial ID:
